Navigation Links
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
Date:10/30/2008

cly update any forward-looking statement, whether as a result of new information, future events or otherwise.

--- FINANCIALS ATTACHED ---

Pharmacyclics, Inc.

(a development stage enterprise)

Condensed Statements of Operations

(unaudited) (in thousands, except per share data)

Three Months Ended

30-Sep

2008 2007

Operating expenses:

Research and development $3,203 $5,240

General and administrative 3,439 2,067

Total operating expenses 6,642 7,307

Loss from operations (6,642) (7,307)

Interest and other, net 100 477

Net loss $(6,542) $(6,830)

Basic and diluted net loss per share $(0.25) $(0.26)

Shares used to compute basic and

diluted net loss per share 26,015 25,958

Condensed Balance Sheets

(unaudited, in thousands)

September 30, June 30,

2008 2008

Assets

Cash, cash equivalents and

marketable securities* $12,467 $16,755

Other current assets 560 401

Total current assets 13,027 17,156

Property and equipment, net 615 6
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
3. Pharmacyclics Announces It Received Nasdaq Notification
4. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) today ... clinical trial to evaluate the objective tumour response ... in patients with advanced cancers. , A total ... (melanoma (5), colorectal (4), gastric (1), pancreas (1), ...
... of probe that allows them to visualize single ribonucleic ... existing methods. The tool will help scientists learn more ... scientists currently use to image these transporters of genetic ... for synthetic RNA or a large number of fluorescent ...
... Nasdaq: PXSL ) today announced the appointment of ... its Board of Directors. , Mr ... Advisors LLC, a,U.S. based fund manager with an investment emphasis ... held a position on the Pharmaxis,share register since 2005. , ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial 3Researchers develop new way to see single RNA molecules inside living cells 2Researchers develop new way to see single RNA molecules inside living cells 3New Pharmaxis Board Appointment 2
(Date:7/9/2014)... nature,s ability to split the water molecule during ... artificial photosynthesis for clean, green and renewable energy ... scientists led by researchers with the Lawrence Berkeley ... Accelerator Laboratory. , Working at SLAC,s Linac ... x-ray laser, the researchers were able to take ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
(Date:7/9/2014)... University of Guelph scientist that involved fitting bumblebees ... to a neonicotinoid pesticide hampers bees, ability to ... Raine, a professor in Guelph,s School of Environmental ... was published July 9 in the British Ecological ... study shows how long-term pesticide exposure affects individual ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bee foraging chronically impaired by pesticide exposure: Study 2
... as it has become known, began on March 11, ... recorded. Following the quake, a 40 to 50-foot tsunami ... estimated 20,000 missing or dead. The massive wave also ... plant. , The release of radioactivity from Fukushimaboth as ...
... may be the 21st century, but nearly half the ... or primitive stoves that burn wood, animal dung, charcoal ... ACS journal Environmental Science & Technology describes ... the obstacles that remain. Susan C. Anenberg ...
... its detection when mixed into meatballs and other food and ... is food for a thoughtful installment of the popular Newscripts ... News . C&EN is the weekly newsmagazine of the American ... Tullo, C&EN senior editor, uses the story to look behind ...
Cached Biology News:Meeting: 'Experts Convene to Examine Impacts of Fukushima on the Ocean' 2
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
5 minutes from gel band to purified DNA...
...
Biology Products: